BLISS GVS PHARMA
|
|
BOM : 506197     NSE : BLISSGVS     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 125.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,312.50 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BLISS GVS PHARMA | -4.1% | 2.3% | 31.6% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF BLISS GVS PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BLISS GVS PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
14.7
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 89.31 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 1.37
P/B Calculated based on Book Value of Rs 959.47 Cr
[Latest Year - Mar2024 - Consolidated Results ] 1.65
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 794.37 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
31% -9% -10% |
SHARE PRICE MOMENTUM OF BLISS GVS PHARMA
BLISS GVS PHARMA vs SENSEX
DEBT OF BLISS GVS PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.07 0.08 0.1 0.08 |
0.09 0.11 0.13 0.11 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BLISS GVS PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BLISS GVS PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-7.31% 21.11% 861.56% 549.88% |
15.12% 41.79% 38.94% 53.8% |
QtrlyTrend |
6 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
BLISS GVS PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
S&P BSE ALLCAP | 1.2% | 1.2% | 40.7% |
S&P BSE MIDSMALLCAP | 1.1% | 1.4% | 56.7% |
S&P BSE SMALL CAP | 0.6% | 1.1% | 55% |
You may also like the below Video Courses
FAQ about BLISS GVS PHARMA
Is BLISS GVS PHARMA good for long term investment?
As on Aug 30,2024, the Fundamentals of BLISS GVS PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of BLISS GVS PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BLISS GVS PHARMA UnderValued or OverValued?
As on Aug 30,2024, BLISS GVS PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of BLISS GVS PHARMA ?
As on Aug 30,2024, the Intrinsic Value of BLISS GVS PHARMA is Rs. 136.84 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 95.36
Fair Value [Median EV / Sales Model] : Rs. 136.84
Fair Value [Median Price / Sales Model] : Rs. 139.50
Estimated Median Fair Value of BLISS GVS PHARMA : Rs. 136.84
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.